CG Oncology, Inc. Common stockCGONNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +45500.00% | -90.17% | -100.00% | +3774.42% | +409.21% |
| Gross Profit Growth | +0.00% | -90.10% | -240.54% | +106.98% | -229.82% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -2.73% | +14.32% | +14.37% | +14.28% | +19.26% |
| Weighted Average Shares Diluted Growth | -2.73% | +14.32% | +14.37% | +14.28% | +19.26% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +748.91% | +0.00% | +0.00% | +275.91% | -11.91% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +278.72% | +25.74% | +24.30% | +32.12% | +4.87% |
| Book Value per Share Growth | +307.99% | +8.35% | +6.11% | +12.10% | -13.95% |
| Debt Growth | -76.89% | +156.44% | +180.00% | +2346.28% | +2850.00% |
| R&D Expense Growth | +68.39% | +59.60% | +69.63% | +42.11% | +11.79% |
| SG&A Expenses Growth | +288.35% | +155.69% | +130.24% | +167.71% | +53.73% |